Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Shares Outstanding (Weighted Average) (2023 - 2026)

Contineum Therapeutics' Shares Outstanding (Weighted Average) history spans 4 years, with the latest figure at $37.3 million for Q1 2026.

  • Quarterly Shares Outstanding (Weighted Average) rose 44.34% to $37.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $37.3 million through Mar 2026, up 44.34% year-over-year, with the annual reading at $27.7 million for FY2025, 43.14% up from the prior year.
  • Shares Outstanding (Weighted Average) came in at $37.3 million for Q1 2026, up from $27.7 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $37.3 million in Q1 2026 to a low of $2.3 million in Q1 2023.
  • The 4-year median for Shares Outstanding (Weighted Average) is $19.4 million (2024), against an average of $16.5 million.
  • The largest YoY upside for Shares Outstanding (Weighted Average) was 1005.94% in 2024 against a maximum downside of 3.53% in 2024.
  • Contineum Therapeutics' Shares Outstanding (Weighted Average) stood at $2.3 million in 2023, then skyrocketed by 738.16% to $19.4 million in 2024, then skyrocketed by 43.14% to $27.7 million in 2025, then skyrocketed by 34.79% to $37.3 million in 2026.
  • Per Business Quant, the three most recent readings for CTNM's Shares Outstanding (Weighted Average) are $37.3 million (Q1 2026), $27.7 million (Q4 2025), and $28.1 million (Q3 2025).